AIM ImmunoTech executed financing agreements to strengthen liquidity, including a Securities Purchase Agreement with institutional investors and a Placement Agency Agreement with Ladenburg Thalmann. The company priced a registered direct offering for approximately $1.3 million at $0.5189 per share and, in a concurrent private placement, issued additional shares plus pre-funded and Class J warrants that could generate about $5.3 million upon cash exercise. Pre-funded warrants are immediately exercisable at $0.001; Class J warrants become exercisable upon stockholder approval at $0.5189 and expire five years after such approval. Ladenburg Thalmann will receive cash fees, expense reimbursement, and placement agent warrants for 306,494 shares at $0.6486.

Agreement 1: AIM ImmunoTech Prices $1.3 Million Registered Direct Offering With $5.3 Million Warrant Upside

• Agreement type: Securities Purchase Agreement for registered direct offering and concurrent private placement
• Counterparty: Institutional investors
• Signed / Effective: Jun 09 2026 / same
• Duration / Termination: At will
• Reason: Raise capital and enhance liquidity

Agreement 2: AIM ImmunoTech Appoints Ladenburg Thalmann as Placement Agent, Issues Warrants and Pays Fees

• Agreement type: Placement agency agreement for the offerings
• Counterparty: Ladenburg Thalmann
• Signed / Effective: Jun 09 2026 / same
• Duration / Termination: At will
• Reason: Facilitate capital raise execution

Original SEC Filing: AIM ImmunoTech Inc. [ AIM ] - 8-K - Jun. 11, 2026